North America dPCR and qPCR Market Forecast to 2030 - Regional Analysis - By Treatment, Product, Application, and End User

The North America dPCR and qPCR market was valued at US$3.55 billion in 2022 and is expected to reach US$7.42 billion by 2030; it is estimated to grow at a CAGR of 9.7% from 2022 to 2030.

Increasing Incidence of Genetic and Infectious Diseases Drive North America dPCR and qPCR Market

According to the National Organization's information on genetic conditions or congenital disabilities, though individual genetic disorders are rare, collectively, they comprise over 15,500 people diagnosed with genetic disorders. In 2022, a report by MJH Life Sciences (US) estimates that 300,000 newborns worldwide are born with sickle cell disease every year, accounting for ? 5% of the global population. In the US, it is one of the most prevalent genetic conditions. Also, 1 in 500 African Americans is affected by sickle cell disease, and ? 1 in 12 of them suffers from the autosomal recessive mutation, according to the CDC. The COVID-19 outbreak had a significant effect on the polymerase chain reaction market growth. The growing demand in the clinical diagnostic market has a favorable effect on the PCR industry. Nearly all diagnostic tests use RT-PCR to test the people having symptoms of COVID-19 and were urged by healthcare experts to undergo a diagnostic test, while the authorities have not endorsed viral culture tests. The majority of biotech and pharmaceutical businesses were concentrating their efforts on research and development divisions to find novel compounds or therapy approaches for COVID-19. In February 2022, Roche added the Cobas 5800 System, a newly released molecular laboratory instrument, to its COVID-19 PCR portfolio for use in nations that accept the CE certification. These product include the cobas SARS-CoV-2 and influenza A/B tests, as well as the cobas SARS-CoV-2 qualitative test. By offering uniform performance and efficiency across low-, medium-, and high-volume molecular laboratory testing needs, these products broaden the Roche Diagnostics molecular portfolio offering. Additionally, healthcare organizations with limited space or resources can have comprehensive access owing to the new, compact Cobas 5800 System. Better testing accessibility will result from this in nations or settings where larger equipment cannot be accommodated due to a lack of resources or space.

Thus, increasing incidence of genetic and infectious diseases in which dPCR and qPCR techniques can be used for diagnosis and treatments support the growth of the North America dPCR and qPCR market.

North America dPCR and qPCR Market Overview

The North America dPCR and qPCR market in North America is segmented into the US, Canada, and Mexico. North America is the largest market for biotechnology, with the US holding the largest market share, followed by Canada. The market growth in North America is attributed to an increase in the demand for innovative products from bio-analytical instrument manufacturers and PCR companies, the presence of key market players, and extensive R&D conducted across various academic and research institutes. The increasing focus on advanced method incorporation in healthcare, government and private initiatives for promoting precision medicine, and massive funds from government and private bodies for genomic research are also expected to stimulate the growth and contribute to exceptional revenue generation for the North America dPCR and qPCR market in North America. Additionally, scientific advances made by various research groups in the country correspond to the growth and dominance of the region in the global market positioning.

North America dPCR and qPCR Market Segmentation

The North America dPCR and qPCR market is segmented based on treatment, product, application, end user, and country.

Based on treatment, the North America dPCR and qPCR market is bifurcated into quantitative PCR (qPCR) and digital PCR (dPCR). The digital PCR (dPCR) segment held a larger share in 2022.

By product, the North America dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share in 2022.

By application, the North America dPCR and qPCR market is segmented into research application, clinical application, and forensic application. The clinical application segment held the largest share in 2022. The clinical application segment is further subsegmented into oncology testing, blood screening, infectious disease testing, and other applications.

By end user, the North America dPCR and qPCR market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held the largest share in 2022.

Based on country, the North America dPCR and qPCR market is segmented into segmented into the US, Canada, and Mexico. The US dominated the North America dPCR and qPCR market in 2022.

Abbott Laboratories, Thermo Fisher Scientific Inc, Takara Bio Inc, Qiagen NV, Standard BioTools Inc, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, and Agilent Technologies Inc are some of the leading companies operating in the North America dPCR and qPCR market.